Even though Vertex's cystic fibrosis revenue is climbing, additional disease areas offer future growth potential that may compensate for any slowdown in sales of older drugs.Vertex's annual revenue has climbed for the past five years, and in spite of the coronavirus slowing some clinical trials, the company has faced limited headwinds from the current health crisis.